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Abstract: As a major regulatory pathway for embryonic development and tissue patterning,
hedgehog signaling is not active in most adult tissues, but is reactivated in a number of
human cancer types. A major milestone in hedgehog signaling in cancer is the Food and
Drug Administration (FDA) approval of a smoothened inhibitor Vismodegib for treatment
of basal cell carcinomas. Vismodegib can block ligand-mediated hedgehog signaling, but
numerous additional clinical trials have failed to show significant improvements in cancer
patients. Amounting evidence indicate that ligand-independent hedgehog signaling plays an
essential role in cancer. Ligand-independent hedgehog signaling, also named non-canonical
hedgehog signaling, generally is not sensitive to smoothened inhibitors. What we know
about non-canonical hedgehog signaling in cancer, and how should we prevent its activation?
In this review, we will summarize recent development of non-canonical hedgehog signaling
in cancer, and will discuss potential ways to prevent this type of hedgehog signaling.
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1. Introduction
For a long time, since its discovery in Drosophila in 1980, hedgehog (Hh) signaling was regarded as an
essential regulator for tissue polarity during development. It was not until 1996, when two independent
research groups discovered somatic inactivating PTCH1 gene mutations in a genetic skin cancer disease,
Gorlin syndrome, and subsequent discovery of activating mutations of smoothened (SMO) in skin cancer
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basal cell carcinomas [1–3]. It is now clear that there are at least four types of human cancer using
activated hedgehog signaling to drive tumor development: basal cell carcinoma, medulloblastoma,
rhabdomyosarcoma [4,5], and meningiomas [6–8].
The current understanding for hedgehog signaling activation in these tumors is described as the
following: In normal situation, PTCH1 functions to suppress smoothened signaling but this suppressive
effect can be relieved when hedgehog ligands bind PTCH1. In these tumors, somatic mutations of
PTCH1 (inactivating) or smoothened (SMO) (activating) result in constitutive activation of the Hh
pathway. Vismodegib, a specific inhibitor for smoothened, has been approved by FDA to treat locally
advanced and metastatic basal cell carcinomas.
Mice with Ptch1 knocked out or with expression of oncogenic SmoM2 develop tumors similar to
Gorlin syndrome patients, BCCs and medulloblastomas. These results provide convincing evidence for
the driver role of Hh signaling for cancer development. In addition, rhabdomyosarcomas frequently
occur in mice after SmoM2 expression or Ptch1 knockout [9–12].
In addition to medulloblastomas and rhabdomyosarcomas, there are numerous types of cancer
associated with Hh signaling activation. However, in each tumor type, the mechanism underlying
the hedgehog signaling activation differs. For example, Ptch1 knockout under the control myeloid
lineage specific cre LysM results in the development of gastrointestinal stromal-like tumors (GIST) [13],
supporting a dominant role of activated Hh signaling for GIST development. On the other hand, in a
small cell lung cancer mouse model, although oncogenic SmoM2 expression is not sufficient to drive
tumor formation, it increases the tumor number. Conversely, mice with Smo knockout have reduced
tumor number [14]. In a Barrett’s esophagus model, Shh expression in the epithelium of esophagus
results in elevated Hh signaling in the stroma [15,16]. The situation in pancreatic cancer is quite different.
It has been shown that SmoM2 has no effects on Kras-induced pancreatic cancer development [17].
Similarly, prostate-specific expression of oncogenic SmoM2 does not lead to formation of prostate
cancer [18]. It needs to be cautious to interpret the negative data because most mouse models only
represent part of cancer progression. For example, the promoting effects on tumor metastasis are hard to
determine because of lack of reliable and robust cancer metastasis models for most cancer types in mice.
2. Hedgehog Signaling Modes of Action in Cancer
We propose three major roles of Hh signaling for cancer development: tumor driving effect,
tumor promoting role, or regulator for residual cancer cells. Numerous studies have demonstrated
a tumor-driving role of activated Hh signaling in BCCs, medulloblastomas, rhabdomyosarcoma,
GIST and Barrett’s esophagus [9,10,13,15,19,20]. In this situation, dysregulation of Hh signaling
alone is able to drive tumor development. Thus, active Hh signaling in those tumors functions
as a tumor driver. For small cell lung cancer (SCLC) at least in the mouse model, activated Hh
signaling can increases the severity of the tumor but this pathway alone is not capable of driving
tumor development [14]. In this situation, Hh signaling is mainly promoting tumor development.
In Kras-driven pancreatic cancer, Hh signaling inhibition has no effects on tumor formation but may
promote cancer metastasis [21–28]. In other situations, active Hh signaling can regulate cancer initiating
cells or the tumor milieu [29,30]. Residual cancer cells are responsible for cancer recurrence after
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chemotherapy, and there is evidence to indicate that Hh signaling may be responsible for maintaining
the residual cell population following therapy.
As to the hedgehog signaling modes of action, at least three types have been reported in human
cancer. First, hedgehog signaling is constitutively activated through somatic gene mutations in genes
like PTCH1, smoothened (SMO) or Su(Fu) (Mode 1). Furthermore, hedgehog signaling can be activated
through over-expression of hedgehog ligand, leading to either paracrine Hh signaling (stromal cells with
activated hedgehog signaling) (Mode 2) or autocrine Hh signaling (cancer cells with activated hedgehog
signaling) (Mode 3). In addition, Hh signaling may also be activated via non-canonical signaling,
through targeting Gli transcriptional factors (transcriptionally or epigenetically) or independent of Gli
transcriptional factors (e.g., regulation of cyclin B1 through PTCH1 [31] or regulation of G-protein
signaling via SMO) [32]. The best way to monitor Hh signaling activation is to detect expression of
putative hedgehog target genes (e.g., GLI1, PTCH1, HIP or SFRP1). In addition, Hh signaling may
synergize with other signaling pathways, including EGF signaling, to regulate certain target genes [33].
Since there are already several reviews on the first three modes of hedgehog signaling in cancer, our
focus will be on the non-canonical signaling mechanisms.
3. Non-Canonical Hedgehog Signaling in Cancer
In normal situation, the transcription factor Gli is activated through ligand binding of PTCH1 and
activation of SMO and this is the canonical Hh signaling pathway. However, in some situations, the
Gli transcription factors can be activated by other molecules/signaling independent of ligand and SMO.
This type of Gli activation is called non-canonical Hh signaling. Non-canonical Hh signaling is mainly
investigated in the context of malignant diseases. The molecules/signaling pathways that can bypass the
ligand-receptor signaling axis to activate Hh signaling pathway include Kras signaling, TGFβ, PI3K,
PKC and epigenetic regulators.
3.1. The RAS-RAF-MEK Signaling Axis
Hedgehog signaling plays a functionally important role in the genesis of Pancreatic ductal
adenocarcinoma (PDAC) [34,35]. However, in the PDAC mouse model with oncogenic Kras expression,
conditional deletion of Smo in ductal cells does not affect GLI1 expression in cancer cells and had no
effects on the multistage development of PDAC tumors [36], indicating that ligand-receptor Hh signaling
is dispensable in pancreatic ductal cells for PDAC progression, and GLI transcription in the neoplastic
ductal cells is regulated through alternative manners. Since Kras mutation presents almost universally in
PDA and is one of the earliest genetic alterations, it is reasonable to speculate that the RAS/RAF/MEK
signaling plays a vital role in the non-canonical activation of Hh signaling in cancer cells.
Indeed, ectopic expression of oncogenic Kras in normal human pancreatic cell line HPDE-c7
can increase transcription activity of Gli molecules [37]. Similar results are also observed after
overexpression of mutant Kras in BxPC3 cells, a pancreatic cancer cell line with wild type Kras [36].
Depletion of oncogenic Kras with Kras-targeted siRNAs resulted in a significant down-regulation
of the transcription activity of GLI, as indicated by GLI1 and PTCH1 mRNAs [37] in PDAC cell
lines in vitro. In gastric cancer cells, the KRAS-MEK-ERK cascade has a positive regulatory role
in GLI transcriptional activity [38]. How RAS/RAF/MEK/MAPK cascade causes activation of Gli1
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transcription remains to be elucidated. It has been reported that GLI transcriptional activity is regulated
by the pattern of Gli phosphorylation [39]. In 3T3 cells, if co-transfected with an activated MEK
construct, the activity of overexpressed GLI1 can be enhanced by 10 times [40], this enhancement was
abolished in an N-terminal deletion mutant of Gli1 lacking the first 130 amino acids [40]; in another
report, it was shown that the Ser130 of Gli1 transcription factor are bound and phosphorylated by
MAPK cascade [41]. Based on these data, it is reasonable to speculate that the transcription activity
of Gli protein could be directly regulated by phosphorylation of the KRAS-MEK-ERK cascade, but this
hypothesis need to be confirmed by further study. On the other hand, Gli activity may also be regulated
by the KRAS-MEK-ERK cascade by preventing Gli protein degradation. It has been reported that
oncogenic Kras blocks proteasome-mediated GLI1 degradation and consequently leads to the activation
of Hh signaling in pancreatic cancer cells [37]. In keratinocytes, ERK1/2 activated by EGFR also
stabilizes GLI proteins, particularly GLI2, by preventing its degradation via the proteasome pathway [33]
(see Figure 1).
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Figure 1. A diagram of typical non-canonical Gli1/2 signaling. There are several ways
for regulating Gli transcriptional factors independent of smoothened and Hh ligands. In
melanomas, Gli2 transcription is regulated by TGFβ signaling. In esophageal cancer, Gli1
can be phosphorylated by S6K to enhance Gli1 transcriptional activity. In BCCs, a typical
PKCi/l can phosphorylate Gli transcription factors to enhance their activities. Previously,
it is reported that PI3K and MEK can regulate Gli transcription factors. In addition to the
positive regulation, PKA and acetyltransferase are known to negatively regulate Gli protein
transcriptional activity. Furthermore, Gli1/2 can also work with downstream effectors of
EGF signaling to control transcription of certain target genes.
Through the RAS/RAF/MEK cascade, it is possible that the up-stream growth factor receptor tyrosine
kinase (RTK) can affect the activity of GLI in a SMO-independent manner or by potentiating the existing
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Hh Signaling. In human normal keratinocytes, EGFR can transduce signal through RAF/MEK/ERK to
cooperate with GLI proteins to selectively regulate some target genes [33], and synergistically induce
oncogenic transformation [42]. These findings have been further confirmed in a transgenic BCC mouse
model and a subcutaneous xenograft model of pancreatic cancer by genetic and pharmacologic inhibition
of EGFR signaling [43], as well as in medulloblastoma [44] and prostate cancer [45]. In NIH3T3 cells,
bFGF stimulates GLI1-luciferase activity in a MEK-1-dependent manner [40], but in medulloblastoma,
FGF is shown as a canonical shh signaling inhibitor in an ERK dependent manner [46], indicating a
significant effect of cellular context in the output of signal interaction (see more in Figure 1).
3.2. TGFβ Signaling Pathway
TGFβ and its receptors are widely expressed in human body, and its signaling plays a major role in
human diseases. During the progression of malignant disorders, TGFβ signaling acts both as a tumor
suppressor and as a tumor promoter depending on tumor context (see review [47]). There is increasing
evidence to show that TGFβ signal transduction is able to interact with the HH pathway downstream
of SMO. Firstly, TGF-β/smad3 cascade was identified as a potent inducer of GLI2 expression and
consequently GLI1 expression in various cancer cell lines, normal fibroblasts and in keratinocytes [48].
Moreover, GLI2 induction by TGFβ is independent from the Hh/Ptch/Smo axis and de novo protein
synthesis [48]. In SMO-deleted pancreatic cancer cell line from mouse, TGFβ treatment leads to marked
elevation of GLI1 and GLI3, even when GLI2 expression is undetectable [36]. In a bone metastasis model
of breast cancer cell MDA-231, Gli2 in cancer cell induces secretion of PTHrP, an important osteolytic
factor, and promotes bone destruction [49]. In this MDA-231 cell line, the SMO mRNA is not detectable,
and GLI2 expression was not repressed by SMO inhibitor cyclopamine but regulated by TGFβ signaling
(see Figure 1). GLI2 expression and osteolytic ability of metastatic tumor can be inhibited by abolishing
TGFβ signaling, indicating SMO-downstream regulation of GLI2 via TGFβ cascade [49]. In a series
of bladder cancer cell lines, it was found that Hh-independent GLI2 expression and function contributes
to invasiveness. The authors suggested that non-canonical GLI2 activity may be attributed to RAS and
TGF-β, both of these pathways being critical for bladder cancer development [50]. In agreement of
these studies, we found TGFβ signaling is critical for Hh signaling-mediated biological functions and
carcinogenesis [51].
All these studies demonstrated that TGFβ signaling is a regulator of Hh cascade independent of SMO
function. To address the mechanism of non-canonical regulation of GLI by TGFβ signaling, Dennler and
colleagues cloned and analyzed human GLI2 promoter and identified a 91 bp region harboring SMAD
and lymphoid enhancer factor/T cell factor binding sites [52]. This study indicates that in response to
TGF-β stimulation, SMAD3 and β-catenin are able to be recruited to the promoter and drive GLI2 gene
transcription. In summary, all these data demonstrate that TGF-β signaling can regulate Gli2 activity by
promoting its transcription directly.
3.3. PKC Signaling
Protein kinase C (PKC) is a family of widely distributed phospholipid-dependent serine/threonine
kinases, which can be divided into 3 groups: conventional or classic PKC isozymes (cPKCs; α, βI, βII,
and γ), novel or non-classic PKC isozymes (nPKCs; δ, ε, η, and θ), and atypical PKC isozymes (aPKCs;
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ζ, ι, and λ). As a receptor for the tumor-promoting phorbol esters, the function of PKC in cancer has
been intensely investigated in the context of cancer [53]. The crosstalk between Hh signaling and PKC
signaling has been reviewed [54].
Here, we mainly discuss the studies about how PKC signaling activates Gli transcription factors
without going through SMO. The role of PKC in Gli activity is controversial. By using LIGHT2 cells,
as well as NIH/3T3 cells, Riobo et al. found that PMA, a classical PKC and novel PKC stimulator,
can induce GLI-luciferase reporter activity in this cell line through PKCδ [40]. This activation can be
blocked by the selective MEK-1 inhibitor PD98059 or the dual MEK-1/2 inhibitor U0126, indicating
that the PKC/MEK/ERK axis drives the activation of GLI upon PMA stimulation. Neill and colleagues
also found that PKCδ promotes GLI1 expression and PKCα decrease GLI1 expression in 293 T
cells independent of MAPK signaling [55]. Cai and colleagues reported that PKCα increases Gli1
activity via MEK/ERK pathway and PKCδ negatively regulates Gli1 expression through transcriptional
down-regulation of GLI1 mRNA in NIH/3T3 cells and human Hepatoma Hep3B Cells [56]. In mouse
BCC cell lines, aPKC-ι/λ was identified as a novel GLI regulator. Although functioning downstream
of SMO, aPKC-ι/λ phosphorylates and activates GLI1, resulting in maximal DNA binding and
transcriptional activation [57]. In addition, aPKCι is also an Hh target gene, and is required for
maximal sustained Hh signaling [57]. In summary, the function of PKC signaling the activation
of non-canonical Hh signaling is complicated and might be cell type dependent or subtype of PKC
dependent (see Figure 1).
3.4. AKT/PI3K Signaling
Riobo and colleagues demonstrated that activation of PI3-kinase/Akt increases Shh-induced Gli
transcriptional activity through antagonizing PKA-dependent Gli2 inactivation in several experimental
systems [58]. Since loss-of-function mutations in the PTEN, a negative regulator of PI3-kinase activity,
occur frequently in human cancer and overexpression of IGF I exists in malignant disease, this study
indicated that activated AKT/PI3K may facilitate Hh signaling pathway and promote tumor formation.
In human PTEN-deficient glioblastomas, Hh signaling is activated [59]. Compensatory up-regulation
of IGF-1R-PI3K is a candidate for the development of Smo antagonist resistant medulloblastoma, and
combination of PI3K inhibitor NVP-BKM120 or the dual PI3K-mTOR inhibitor NVP-BEZ235 with the
Smo antagonist markedly delayed the development of resistance [60].
In mouse melanoma cells, COS7 cells, human prostate cancer LNCaP cells and human glioma U87
cells, the acquisition of oncogenic RAS-RAF-MEK and/or AKT signaling could be responsible for
cell-intrinsic enhancement of GLI1 transcriptional activity driven by enhanced nuclear localization and
transcriptional activity [61].
3.5. TNFα/mTOR Pathway
In a recent study in esophageal adenocarcinomas, it was revealed that GLI1 activity can be enhanced
by TNFα/mTOR pathway independent of SMO activity [62]. TNFα induces mTOR activation, and then
mTOR phosphorylates its target S6K1. GLI1 protein can be phosphorylated by activated S6K1 at ser84,
and this phosphorylation enhances GLI1 function by attenuating SuFu-mediated Gli1 inhibition [62].
This study also confirmed the importance of phosphorylation in the regulation of GLI proteins function.
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3.6. Epigenetic Regulation of GLI
Cancer epigenetics is a rapidly developing field of cancer research since more and more epigenetic
regulators are found mutated in malignant diseases and more and more evidence is showing the important
role of epigenetic dysregulation in cancer growth and metastasis. Not surprising, many compounds have
been reported targeting components of the epigenetic machineries for cancer therapy.
Recently there are some data showing that Hh pathway can be regulated epigenetically during
cancer development. SNF5, a tumor suppressor, is core component of the SWI-SNF chromatin
remodeling complex. Jagani and coworkers found that SNF5 interacts with GLI1 and is enriched at
Gli1-regulated promoter region [63]. Inactivation of SNF5 results in constitutive up-regulation of GLI1
transcriptional activity in malignant rhabdoid tumors cells in vivo and in vitro [63]. Although detailed
mechanisms remain unclear, this study provided a link between abnormal activation of the Hh pathway
and deregulated chromatin remodeling in tumor development.
Multiple endocrine neoplasia type 1 (MEN-1 syndrome), a hereditary condition associated with
tumors of the endocrine (hormone producing) glands, and the tumor suppressor gene MEN1 is
frequently mutated in this disease. Gurung and colleagues found that menin combines with
Gli1 promoter, and recruits protein arginine methyltransferase 5 (PRMT5) to promote repressive
histone arginine methylation, leading to decreased Gli1 expression independent of the canonical
GAS1/PTCH1/SMO-mediated Hh signaling [64]. This study revealed a novel non-canonical manner
controlling the levels of GLI1 via a menin-mediated epigenetic pathway, and provided a possible
mechanism of tumor development of MEN-1 disease, and a rationale for directly inhibiting GLI1 for
treating these tumors. Malatesta et al. reported that p300/CREB-binding protein-associated factor
(PCAF), a histone acetyltransferase, interacts with GLI1 and is recruited to the promoter of GLI1
responsive gene leading to H3K9 acetylation of Hh target gene promoters and their activation in
medulloblastoma and glioblastoma cells, and PCAF downregulation in these cells leads to decreased
proliferation and increased apoptosis [65]. However, in hepatocellular carcinoma (HCC) cells, PCAF
suppresses Hh signaling by directly acetylating cytoplasmic GLI1 protein at lysine 518, preventing its
nuclear translocation and promoter occupancy [66], whereas deacetylation of Gli1 and Gli2 by histone
deacetylases (HDAC) promotes their transcriptional activation in medulloblastoma [67].
BRD4, a conserved member of the bromodomain and extraterminal (BET) family of chromatin
readers, plays a critical role in transcription by binding acetylated histones and recruiting transcriptional
complexes [68]. Recently, two groups revealed that BRD4 and other BET members can occupy GLI1
and GLI2 promoters directly, and enhance their transcription [69,70]. BRD4 inhibitor JQ1 or I-BET151
treatment inhibits GLI1 and GLI2 expression and growth of hedgehog-driven tumors in vitro and in vivo,
such as basal cell carcinoma, medulloblastoma and atypical teratoid rhabdoid tumor [69,70]. However,
the details how BRD4 is regulated and involves in Gli activation, and whether BRD4 facilitates Hh
independent non-canonical Gli regulation are needed for further investigation.
3.7. Other Non-Canonical Regulations of Hedgehog Signaling
Ewing sarcoma family of tumors (ESFT) is characterized by producing an aberrant fusion gene
EWS-FLI1 resulting from the chromosomal translocation t(11;22). EWS-FLI1 can induce GLI1
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transcription by direct binding to the Gli1 promoter, and overexpressed GLI1 is an important mediator
in ESFT development [71]. Earlier study has revealed direct binding of PTCH1 with cyclinB1 in cancer
cells, leading to delayed cell cycling [31]. Several studies have indicated signaling of SMO to G-proteins,
which is independent of Gli transcription factors [32,72]. How much this G-protein coupling is involved
in cancer development is still an unanswered question.
Gli1 activity is also regulated by energy sensor, AMP-activated protein kinase (AMPK). Recently,
Li et al. reported that in the situation of insufficient cellular energy, AMPK is activated by accumulated
ADP and AMP, and then phosphorylates directly GLI1 at serines 102 and 408 and threonine 1074,
leading to suppression of GLI1 transcription activity. In this manner, when energy stores are inadequate,
cells or organs slow or postpone developmental steps driven by Hh signaling in order to enhance the
chance of survival of a growing animal [73]. In medulloblastoma, this mechanism of Gli1 regulation
also exists, and mutation of these three phosphorylation sites may prevent phosphorylation by AMPK
and leads to increased GLI1 protein stability, transcriptional activity, and oncogenic ability.
4. Conclusions
It is clear that regulation of Gli transcription factors is not only restricted to the canonical
Hh/SMO-dependent cascade but also through the convergence of multiple SMO-independent pathways.
These findings not only explain the ineffectiveness and failed clinical trials using SMO antagonists, and
also encourage developing new strategies to suppress non-canonical Hh signaling.
Unlike the canonical pathway, there are different ways by which non-canonical Hh signaling can
occur. In some cancer types, more than one type of non-canonical Hh signaling may co-exist. Thus,
there is a need of paradigm shift in designing strategies to block hedgehog signaling in cancer.
First, canonical Hh signaling in cancer is quite limited to tumors with gene mutations in PTCH1
and SMO, which will be sensitive to SMO signaling inhibitors. In most cancer cells, one or more
non-canonical Hh signaling modes of action play a critical role in cancer development. Thus, there is an
urgent need to understand the specific non-canonical signaling mechanism in a given tumor type before
novel mitigation strategies can be established.
Second, due to the co-existence of activation of multiple signaling pathways in a given cancer types,
as well as different mechanisms of non-canonical Hh signaling, combined target therapy will be more
effective in suppressing tumor progression.
Third, despite the existence of multiple aberrant signaling in a given cancer cells, each alteration
may affect different stages of cancer development. Thus, physiologically relevant mouse models will be
needed to test the role of each aberrant signaling.
Taken together, we believe that the unsuccessful clinical trials using SMO signaling inhibitors have
revealed novel mechanisms underlying Hh signaling activation in cancer, particularly non-canonical Hh
signaling. Thus, inhibition of Hh signaling at the level of GLI transcription factors, rather than the
level of SMO, might be a more effective way to combat cancer [74–77]. Our efforts in understanding
non-canonical Hh signaling may lead to novel strategies to treat cancer.
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